Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Surg Obes Relat Dis. 2018 Nov 2;15(1):36–42. doi: 10.1016/j.soard.2018.10.021

Table 1.

Characteristics of the study participants, changes in glucose and BAC

Mean (SD)
Study 1 (n=5) Study 2 (n=8)
Characteristics Before RYGB After RYGB RYGB 1–5 yr
Age, yr 44.7 (4.6) 45.5 (4.7) 42.5 (8.0)
Weight, kg 109.3 (15.0) 79.1 (19.1) 80.8 (14.1)
BMI, kg/m2 42.9 (4.7) 31.1 (6.9) 30.0 (5.2)
FFM, kg 51.4 (5.8) 46.6 (5.8) 49.4 (5.7)
Co-morbidities (%)
 Hypertension 40.0 20.0 0.0
 Hypercholesterolemia 20.0 20.0 12.5
 Depression 40.0 40.0 37.5
Menopause Status (%)
 Pre-menopausal 80.0 80.0 62.5
 Post-menopausal 0.0 0.0 12.5
 Uncertain§ 20.0 20.0 25.0
Glucose Nadir, mg/dl
 Placebo −0.4 (1.0) −1.0 (1.6) −1.0 (1.0)
 Alcohol −9.6 (1.5) −5.5 (2.6) −6.3 (3.4)
Glucose Peak, mg/dl
 Placebo 5.6 (3.6) 4.4 (2.3) 5.8 (2.5)
 Alcohol 2.6 (2.5) 7.7 (4.6) 10.7 (4.6)
Alcohol-related variables
 Peak BAC (g/L) 0.58 (0.09) 1.23 (0.2) 1.10 (0.17)
 Time to peak BAC (min)* 36.1 (15.8) 15.0 (0.0) 15.0 (0.0)
 Area under the BAC-time curve (g·l−1 min) 99.3 (6.7) 173.5 (30.5) 151.2 (7.2)

SD = standard deviation; RYGB = Roux-en-Y gastric bypass; BMI = Body mass index (calculated as weight in kilograms divided by height in meter squared); FFM = fat free mass. BAC = blood alcohol concentration; % = percentage

*

From the time of the first sip of the drink, which was ingested over 10 min.

§

Three patients had hysterectomy. One was on hormone replacement treatment.

The present study is underpowered to detect clinically meaningful difference

Values are represented in means (SD).

different from placebo (P < .01).

different from Before RYGB (P <.05)